Last 48 quarters of trend data · Healthcare · Specialty & Generic Drugs
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
| Metric | TTM | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | 73.75 | — | 21.67 | 10.67 | 12.72 | 8.08 | — | — | 9.90 | 8.14 | 10.72 | — | 21.65 | 15.12 | 20.39 | 35.18 | — | — | 70.91 | 1485.40 | — |
| — | — | — | — | +28.5% | -0.8% | — | — | -54.3% | -46.1% | -47.4% | — | — | — | -71.2% | -97.6% | — | — | — | +7454.9% | — | |
| P/S Ratio | 3.13 | 3.01 | 3.46 | 2.92 | 2.16 | 1.80 | 1.55 | 2.11 | 1.74 | 1.67 | 1.81 | 2.09 | 2.12 | 2.37 | 2.38 | 3.02 | 2.58 | 2.22 | 2.65 | 3.01 | 2.18 |
| — | +67.1% | +122.9% | +38.6% | +24.3% | +8.1% | -14.4% | +1.0% | -17.8% | -29.7% | -23.8% | -30.9% | -18.0% | +6.7% | -10.2% | +0.5% | +18.3% | -6.6% | -24.5% | -23.8% | -38.4% | |
| P/B Ratio | 3.32 | 3.57 | 3.48 | 2.76 | 2.40 | 2.05 | 1.75 | 1.81 | 1.85 | 1.69 | 1.97 | 2.04 | 2.29 | 2.64 | 2.59 | 3.24 | 3.26 | 3.05 | 3.09 | 2.71 | 1.98 |
| — | +74.2% | +98.8% | +52.0% | +29.8% | +21.5% | -11.3% | -11.0% | -19.3% | -36.2% | -23.6% | -37.1% | -29.6% | -13.2% | -16.4% | +19.3% | +64.7% | +50.5% | +21.0% | +7.4% | -23.4% | |
| P/FCF | 9.38 | 7.64 | 10.52 | 8.04 | 8.73 | 4.42 | 16.09 | 4.84 | 4.91 | 4.54 | 5.73 | 7.23 | 15.39 | 7.62 | 7.83 | 8.52 | 7.55 | 4.95 | 8.51 | 12.45 | 11.67 |
| — | +73.0% | -34.7% | +66.1% | +77.7% | -2.6% | +180.9% | -33.1% | -68.1% | -40.5% | -26.8% | -15.1% | +103.8% | +54.0% | -8.0% | -31.6% | -35.3% | -34.1% | -88.9% | +46.7% | -9.9% | |
| EV / EBITDA | 11.20 | — | 11.42 | 10.16 | 3.31 | 13.06 | — | 25.53 | 7.88 | 6.48 | 8.18 | 12.93 | 11.41 | 10.22 | 10.75 | 13.62 | — | 19.22 | 15.82 | 14.43 | 15.65 |
| — | — | — | -60.2% | -58.0% | +101.6% | — | +97.5% | -30.9% | -36.6% | -23.8% | -5.1% | — | -46.8% | -32.1% | -5.6% | — | +10.0% | -70.3% | +39.1% | +44.4% | |
| EV / EBIT | 83.68 | — | 19.66 | 11.08 | 14.19 | 53.43 | — | — | 12.39 | 10.63 | 14.84 | 28.23 | 13.70 | 19.85 | 21.62 | 20.58 | 14.04 | 22.52 | 23.76 | 23.94 | 9.49 |
| — | — | — | — | +14.6% | +402.6% | — | — | -9.6% | -46.4% | -31.4% | +37.1% | -2.4% | -11.9% | -9.0% | -14.0% | +47.9% | -81.3% | — | +59.2% | -25.2% |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
| Metric | TTM | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 88.2% | 91.1% | 90.4% | 71.3% | 97.9% | 77.1% | 88.9% | 88.3% | 88.2% | 89.4% | 89.3% | 89.4% | 89.4% | 89.5% | 89.8% | 85.6% | 82.8% | 85.8% | 86.7% | 85.8% | 84.8% |
| — | +18.1% | +1.7% | -19.3% | +11.1% | -13.8% | -0.4% | -1.2% | -1.4% | -0.1% | -0.6% | +4.5% | +8.0% | +4.3% | +3.6% | -0.3% | -2.4% | +3.8% | +3.0% | -8.1% | -8.3% | |
| Operating Margin | 5.3% | -33.3% | 20.5% | 20.0% | 75.9% | 5.1% | -65.6% | -6.2% | 17.5% | 24.7% | 19.5% | 7.3% | 12.1% | 17.7% | 16.5% | 14.1% | -27.1% | 2.6% | 9.2% | 10.8% | 5.5% |
| — | -751.2% | +131.3% | +421.3% | +332.9% | -79.3% | -437.0% | -184.8% | +44.8% | +39.1% | +18.3% | -48.0% | +144.7% | +573.6% | +79.6% | +31.2% | -592.0% | -22.2% | +199.1% | -59.7% | -78.9% | |
| Net Margin | -8.3% | -38.9% | 16.0% | 27.4% | 17.0% | 22.3% | -68.7% | -10.3% | 17.6% | 20.4% | 16.5% | -1.6% | 9.3% | 15.1% | 10.9% | 7.8% | -24.7% | -2.1% | 3.7% | 0.2% | -3.9% |
| — | -274.2% | +123.2% | +366.0% | -3.3% | +9.5% | -517.3% | -536.0% | +88.8% | +35.0% | +50.9% | -120.8% | +137.7% | +823.0% | +193.6% | +3741.6% | -526.1% | +66.9% | +107.7% | -99.0% | -119.7% |
| Metric | TTM | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -8.5% | -10.8% | 4.1% | 6.6% | 4.9% | 6.6% | -18.2% | -2.2% | 4.6% | 5.4% | 4.5% | -0.4% | 2.6% | 4.2% | 3.0% | 2.2% | -8.2% | -0.7% | 1.0% | 0.0% | -0.9% |
| — | -263.9% | +122.7% | +395.9% | +6.3% | +21.0% | -503.4% | -469.1% | +77.5% | +29.5% | +48.5% | -118.2% | +131.7% | +733.4% | +199.0% | +4871.0% | -820.1% | +49.5% | +111.1% | -98.7% | -123.6% | |
| ROA | -3.0% | -4.2% | 1.7% | 2.5% | 1.8% | 2.3% | -6.4% | -0.8% | 1.6% | 1.8% | 1.5% | -0.1% | 0.8% | 1.3% | 0.9% | 0.6% | -2.3% | -0.2% | 0.3% | 0.0% | -0.3% |
| — | -285.8% | +126.3% | +417.1% | +12.2% | +23.8% | -530.2% | -510.7% | +89.0% | +39.3% | +58.7% | -120.3% | +136.8% | +817.8% | +210.2% | +4531.4% | -692.4% | +55.7% | +108.3% | -99.3% | -113.7% | |
| ROIC | 2.1% | -4.0% | 2.4% | 1.9% | 8.3% | 0.5% | -6.6% | -0.5% | 1.8% | 2.4% | 1.8% | 0.6% | 1.2% | 1.6% | 1.5% | 1.2% | -2.5% | 0.2% | 0.7% | 0.7% | 0.4% |
| — | -851.9% | +136.1% | +462.0% | +362.0% | -77.6% | -456.3% | -187.0% | +55.5% | +47.6% | +24.8% | -47.7% | +145.8% | +610.8% | +105.2% | +69.0% | -750.1% | +5.9% | +197.2% | -74.7% | -85.6% |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
| Metric | TTM | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 1.26 | 1.35 | 0.92 | 1.20 | 1.26 | 1.37 | 1.47 | 1.30 | 1.51 | 1.49 | 1.54 | 1.57 | 1.55 | 1.66 | 1.65 | 1.74 | 1.88 | 2.12 | 1.91 | 1.70 | 1.55 |
| — | -1.8% | -37.4% | -7.9% | -16.6% | -7.8% | -4.8% | -17.1% | -2.9% | -10.5% | -6.4% | -10.2% | -17.7% | -21.6% | -13.9% | +2.7% | +21.4% | +30.7% | +14.1% | +186.2% | +152.5% | |
| Debt / EBITDA | 5.89 | — | 10.32 | 13.71 | 4.98 | 23.03 | — | 49.73 | 17.16 | 14.58 | 15.98 | 25.20 | 20.56 | 17.30 | 18.28 | 20.50 | — | 33.50 | 25.29 | 22.91 | 28.75 |
| — | — | — | -72.4% | -71.0% | +58.0% | — | +97.4% | -16.6% | -15.7% | -12.6% | +22.9% | — | -48.4% | -27.7% | -10.5% | — | +2.8% | -71.6% | +139.2% | +213.3% | |
| Current Ratio | 1.86 | 1.82 | 1.78 | 2.04 | 1.86 | 1.65 | 1.62 | 3.38 | 4.46 | 4.26 | 2.37 | 2.27 | 2.24 | 2.06 | 3.18 | 3.06 | 2.79 | 3.16 | 3.67 | 3.39 | 3.23 |
| — | +10.3% | +10.0% | -39.6% | -58.3% | -61.3% | -31.6% | +49.0% | +99.4% | +106.6% | -25.7% | -26.0% | -19.9% | -34.8% | -13.3% | -9.7% | -13.4% | -11.5% | +9.5% | -19.5% | -25.7% | |
| Quick Ratio | 1.67 | 1.64 | 1.58 | 1.85 | 1.67 | 1.44 | 1.37 | 2.97 | 3.99 | 3.74 | 2.02 | 1.90 | 1.85 | 1.67 | 2.49 | 2.32 | 2.03 | 2.27 | 2.45 | 2.06 | 1.90 |
| — | +14.1% | +15.0% | -37.9% | -58.1% | -61.5% | -31.9% | +56.8% | +116.3% | +123.3% | -18.9% | -18.3% | -8.9% | -26.2% | +1.5% | +13.0% | +6.6% | +11.8% | +26.8% | -49.3% | -54.7% | |
| Interest Coverage | -2.22 | -9.09 | 6.69 | 5.73 | 5.59 | 1.19 | -14.53 | -0.48 | 4.46 | 4.42 | 3.22 | 1.59 | 3.34 | 2.41 | 2.15 | 2.53 | 3.60 | 1.85 | 2.55 | 2.28 | 3.98 |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 48 years · Updated daily
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying JAZZ stock.
Jazz Pharmaceuticals plc's current P/E is 73.7x. The average P/E over the last 3 quarters is 15.0x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
Jazz Pharmaceuticals plc's current operating margin is 5.3%. Margins have been compressing over recent quarters. Quarterly margins are particularly useful for identifying trend inflections that annual data smooths over.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking Jazz Pharmaceuticals plc's business trajectory between earnings reports.